Jiangsu HengRui Medicine Co., Ltd.: Pancreatic Neoplasms trials
The registry lists 11 Pancreatic Neoplasms studies with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor. 3 are open to participants now and 0 have results posted.
Phase 1 6Phase 2 5Phase 3 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid TumorsRecruitingNCT07806058Phase 1/2
- An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic CancerRecruitingNCT07589569Phase 2
- HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic CancerRecruitingNCT05751850Phase 3
- Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic CancerCompletedNCT05074589Phase 3
- A Trial of SHR-A1904 in Patients With Advanced Pancreatic CancerStatus unknownNCT04928625Phase 1
- A Study of Irinotecan Liposome in Advanced Pancreatic CancerCompletedNCT04796948Phase 1
- A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic CancerCompletedNCT04624217Phase 1/2
- A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic CancerStatus unknownNCT04425876Phase 1
- A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyTerminatedNCT04300114Phase 3
- A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic CancerCompletedNCT04228601Phase 1/2
- A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine TumorTerminatedNCT01994213Phase 2